OncoMatch/Clinical Trials/NCT03617133
Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer
Is NCT03617133 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Systemic application of simultaneous chemotherapy for uterine cervical neoplasms.
Treatment: Systemic application of simultaneous chemotherapy — The research group on adaptive image-guided radiotherapy for locally advanced cervical carcinoma completed the protocol for the EMBRACE II study in October 2018. This study will be carried out in the next few years at the University Clinic for Radiotherapy at the Medical University of Vienna and other international partner institutes. EMBRACE II builds on the findings of the current EMBRACE study. These are already implemented in everyday clinical practice in order to further improve the accuracy of the entire therapy of cervical carcinomas, using state-of-the-art techniques of tele- and brachytherapy. The aim of the EMBRACE II study is to maintain and enhance the excellent local tumor control as well as the nodal and systemic control for all tumor stages while minimizing the adverse reaction rates for all affected organs (rectum, sigmoid, urinary bladder, and vagina) to increase the quality of life of patients with cervical carcinomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Prior therapy
Cannot have received: pelvic or abdominal radiotherapy
Previous pelvic or abdominal radiotherapy
Cannot have received: total or partial hysterectomy
Previous total or partial hysterectomy
Cannot have received: combination of preoperative radiotherapy with surgery
Combination of preoperative radiotherapy with surgery
Cannot have received: brachytherapy only
Patients receiving BT only
Cannot have received: external beam radiotherapy only
Patients receiving EBRT only
Cannot have received: neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin
Exception: adjuvant chemotherapy in the form of 4 courses of 3 weekly Carboplatin (AUC 5) and Paclitaxel (155 mg/m2) is allowed according to departmental policy
Patients receiving neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg/2). However, adjuvant chemotherapy in the form of 4 courses of 3 weekly Carboplatin (AUC 5) and Paclitaxel (155 mg/m2) is allowed according to departmental policy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify